

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM550452

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	NUNC PRO TUNC ASSIGNMENT		
<b>EFFECTIVE DATE:</b>	08/29/2019		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Nektar Therapeutics		11/21/2019	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Inheris Pharmaceuticals, Inc.		
<b>Street Address:</b>	150 North Riverside Plaza, Suite 1840		
<b>City:</b>	Chicago		
<b>State/Country:</b>	ILLINOIS		
<b>Postal Code:</b>	60606		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	88232942	INHERIS	
<b>Serial Number:</b>	88020231	KYVIDAS	
<b>Serial Number:</b>	88444963	KYVODA	
<b>Serial Number:</b>	88020226	RYNCLESS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	4048156555		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	4152734319		
<b>Email:</b>	tadmin@kilpatricktownsend.com		
<b>Correspondent Name:</b>	Jennifer D. Arkowitz		
<b>Address Line 1:</b>	1100 Peachtree Street, Suite 2800		
<b>Address Line 2:</b>	Mailstop: IP Docketing - 22		
<b>Address Line 4:</b>	Atlanta, GEORGIA 30309		
<b>ATTORNEY DOCKET NUMBER:</b>	1117961		
<b>NAME OF SUBMITTER:</b>	Amy Wells		
<b>SIGNATURE:</b>	/Amy M. Wells/		
<b>DATE SIGNED:</b>	11/21/2019		

OP \$115.00 88232942

**Total Attachments: 4**

source=Confirmatory Trademark Assignment#page1.tif

source=Confirmatory Trademark Assignment#page2.tif

source=Confirmatory Trademark Assignment#page3.tif

source=Confirmatory Trademark Assignment#page4.tif

**CONFIRMATORY TRADEMARK ASSIGNMENT**

THIS CONFIRMATORY ASSIGNMENT, made and entered into nunc pro tunc as of August 29, 2019, by and between Nektar Therapeutics, a Corporation organized under the laws of Delaware, U.S.A. with a principal place of business at 455 Mission Bay Boulevard South, San Francisco, California 94158, U.S.A. ("Assignor"), and Inheris Pharmaceuticals, Inc., a Corporation organized under the laws of Delaware, U.S.A. with a principal place of business at 150 North Riverside Plaza, Suite 1840, Chicago, Illinois 60606, U.S.A. ("Assignee").

WHEREAS, the Assignor has a bona fide intent to use the marks set forth on the attached **Schedule A** in the United States and has filed for federal trademark applications for the Trademarks on an intent-to-use basis ("Applications");

WHEREAS the Assignor is the owner of the trademarks listed in the attached **Schedule A** and is the owner of the applications and registrations listed in the Schedule; and

WHEREAS, pursuant to a certain Share Purchase and Transfer of Assets Agreement, effective as of August 29, 2019, between Inheris Pharmaceuticals, Inc. and all equity shareholders of Nektar Therapeutics, Assignee acquired all of Assignor's right, title, and interest in and to the Trademarks listed on **Schedule A** and the goodwill associated therewith; and

WHEREAS, Assignee, as a successor to that portion of the business of Assignor associated with the listed Trademarks and Applications, which is ongoing and existing, has acquired all of Assignor's rights in and to the Trademarks and Applications; and

WHEREAS, Assignee is desirous of accepting said assignment.

NOW THEREFORE, in consideration of one dollar (\$1.00), and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor hereby confirms the assignment to the Assignee of full right to and title in the Assigned IP together with the goodwill of the business symbolized by the Assigned IP and the right to recover for damages and profits and all other remedies for past infringements thereof, *nunc pro tunc* as of August 29, 2019. Assignor further authorizes the Assignee to proceed with the recordal before the necessary national and international Trademark Offices.

Nektar Therapeutics

Mark A. Wilson

By: Mark A. Wilson

Title: SVP & General Counsel

Date: November 21, 2019

Inheris Pharmaceuticals, Inc.

Mark A. Wilson

By: Mark A. Wilson

Title: Corporate Secretary

Date: November 21, 2019

**Schedule A**

<b>Mark</b>	<b>Country</b>	<b>Status</b>	<b>App. No. App. Date</b>	<b>Reg. No. Reg. Date</b>
INHERIS	Australia	Pending	(IR1480655) Jun 17, 2019	
INHERIS	Canada	Pending	(IR1480655) Jun 17, 2019	
INHERIS	China	Pending	(IR1480655) Jun 17, 2019	
INHERIS	European Union	Published	(IR1480655) Jun 17, 2019	
INHERIS	International Bureau (WIPO)	Registered	1480655 Jun 17, 2019	1480655 Jun 17, 2019
INHERIS	Israel	Pending	(IR1480655) Jun 17, 2019	
INHERIS	Japan	Pending	(IR1480655) Jun 17, 2019	
INHERIS	Mexico	Pending	(IR1480655) Jun 17, 2019	
INHERIS	Republic of Korea	Pending	(IR1480655) Jun 17, 2019	
INHERIS	United Kingdom	Registered	(IR1480655) Jun 17, 2019	1480655 Jun 17, 2019
INHERIS	United States of America	Allowed	88232942 Dec 18, 2018	
KYVIDAS	Australia	Registered	1987992(IR1448174) Dec 26, 2018	1448174 Dec 26, 2018
KYVIDAS	Canada	Pending	1938154 Dec 27, 2018	

**Schedule A**

<b>Mark</b>	<b>Country</b>	<b>Status</b>	<b>App. No. App. Date</b>	<b>Reg. No. Reg. Date</b>
KYVIDAS	China	Registered	(IR1448174) Dec 26, 2018	1448174 Dec 26, 2018
KYVIDAS	European Union	Registered	(IR1448174) Dec 26, 2018	1448174 Dec 26, 2018
KYVIDAS	India	Registered	4088753(IR1448174) Dec 26, 2018	1448174 Dec 26, 2018
KYVIDAS	International Bureau (WIPO)	Registered	1448174 Dec 26, 2018	1448174 Dec 26, 2018
KYVIDAS	Japan	Pending	(IR1448174) Dec 26, 2018	
KYVIDAS	Mexico	Pending	(IR1448174) Dec 26, 2018	
KYVIDAS	Switzerland	Pending	(IR1448174) Dec 26, 2018	
KYVIDAS	United States of America	Allowed	88020231 Jun 29, 2018	
KYVODA	United States	Allowed	88444963 May 24, 2019	
RYNCLESS	Australia	Registered	1987998(IR1448175) Dec 26, 2018	1448175 Dec 26, 2018
RYNCLESS	Canada	Pending	1938153 Dec 27, 2018	
RYNCLESS	China	Pending	(IR1448175) Dec 26, 2018	
RYNCLESS	European Union	Registered	(IR1448175) Dec 26, 2018	1448175 Dec 26, 2018

**Schedule A**

<b>Mark</b>	<b>Country</b>	<b>Status</b>	<b>App. No. App. Date</b>	<b>Reg. No. Reg. Date</b>
RYNCLESS	India	Registered	4087333(IR1448175) Dec 26, 2018	1448175 Dec 26, 2018
RYNCLESS	International Bureau (WIPO)	Registered	1448175 Dec 26, 2018	1448175 Dec 26, 2018
RYNCLESS	Japan	Pending	(IR1448175) Dec 26, 2018	
RYNCLESS	Mexico	Pending	(IR1448175) Dec 26, 2018	
RYNCLESS	Switzerland	Pending	(IR1448175) Dec 26, 2018	
RYNCLESS	United States of America	Allowed	88020226 Jun 29, 2018	